UCB

Phone: +613 9828 1800 Option 3

Fax: +61 3 9828 1860

E-mail: ucbcares.au@ucb.com, ds.au@ucb.com

Web: https://ucbaustralia.com.au/

Type	Société anonyme
Traded as	Euronext Brussels: UCB BEL 20 component
Industry	Pharmaceuticals
Predecessor	Compagnie Continentale du Pégamoïd Union des Fabriques Belges de Textiles Artificiels
Founded	1928
Headquarters	Brussels, Belgium
Key people	Gerhard Mayr (Chairman), Jean Christophe Tellier (CEO)
Products	Biopharmaceuticals
Revenue	€ 5.777 billion (2021)
Operating income	€ 1.109 billion (2018)
Net income	€ 0.823 billion (2018)
Number of employees	7,600 (2020)
Website	www.ucb.com

A global biopharma company, focusing on neurology and immunology. Our business is strong. Total revenue grew to €4.9 billion in 2019. We are more than 7,600 people in all four corners of the globe, inspired by patients and driven by science. UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are Inspired by Patients. Driven by Science. UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives

For detailed contact information visit location pages below.